All In Biotech

Drug Trial Radar · NCT05853354

Comparative Efficacy, Safety, PK, and Immunogenicity Study

A Randomized, Double-blind, Parallel-group, Active-controlled Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of LY06006 Compared With EU-Prolia in Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Apr 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 392 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

392

Planned (sponsor's estimate)

Start

Apr 5, 2023

Primary completion

Jul 30, 2025

Study completion Dec 30, 2025

Sponsor

Lead sponsor
Luye Pharma Group Ltd.Industry
Sponsor type
Industry
First posted
May 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 60 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

Conditions

  • Osteoporosis, Postmenopausal

Interventions

  • DenosumabBiological

    Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate equivalent efficacy between LY06006 and EU-Prolia, in terms of BMD in female participants with postmenopausal osteoporosis;Time frame: 12 months
  2. EU Marketing Authorization only: To demonstrate similar PD between LY06006 and EU-Prolia, in terms of the bone resorption marker sCTX in female participants with postmenopausal osteoporosisTime frame: 6 months

Locations

39 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trials Management Services, LLC

    Thousand Oaks, California

  • Indago Research and Health Center, Inc.

    Hialeah, Florida

  • Valley Institute of Research

    Fort Worth, Texas

  • MHAT Dr. Atanas Dafovski AD

    Kardzhali, Bulgaria

  • Medical Centre Leo Clinic EOOD

    Plovdiv, Bulgaria

  • Diagnostic-consultative center Ascendent EOOD

    Sofia, Bulgaria

  • Medical Center Leo Clinic EOOD

    Varna, Bulgaria

  • CCR Brno s.r.o.

    Brno, Czechia

  • Synexus Prague

    Prague, Czechia

  • Gifu Prefectural General Med C.

    Gifu, Gihu, Japan

  • Asakawa Orthopedic Clinic

    Chikugo, Hukuoka, Japan

  • Obase Hospital - Orthopedics

    Miyako-gun, Hukuoka, Japan

  • Himeno Hospital

    Yame-gun, Hukuoka, Japan

  • Marunouchi Hospital

    Matsumoto-shi, Nagano, Japan

  • Nakamura Hospital

    Beppu, Ôita, Japan

  • Nemoto Geka SeikeiGeka

    Fujimi, Saitama, Japan

  • Kobayakawa Orthopedic Rheumatologic

    Fukuroi, Shizuoka, Japan

  • Med Teda Ooimachi Orthopaedic

    Shinagawa-ku, Tôkyô, Japan

  • Koenji Orthopedic Surgery

    Shinagawa-ku, Tôkyô, Japan

  • Shimonoseki City Hospital

    Shimonoseki, Yamaguchi, Japan

  • Centrum Medyczne Pratia Czestochowa

    Częstochowa, Poland

  • Synexus Polska Sp. z o.o.

    Częstochowa, Poland

  • Synexus Polska Sp. z o.o.

    Gdansk, Poland

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Poland

  • Pratia Jelenia Gora

    Jelenia Góra, Poland

  • Centrum Medyczne Pratia Katowice

    Katowice, Poland

  • Pratia MCM Krakow

    Krakow, Poland

  • Krakowskie Centrum Medyczne Sp.z o.o.

    Krakow, Poland

  • Synexus Polska Sp. z. o.o.

    Lodz, Poland

  • Centrum Medyczne AMED Oddzial w Lodzi

    Lodz, Poland

  • Synexus Polska Sp. z o.o.

    Poznan, Poland

  • FutureMeds Warszawa Centrum

    Warsaw, Poland

  • Synexus Polska Sp. z o.o.

    Warsaw, Poland

  • Centrum Medyczne AMED

    Warsaw, Poland

  • Synexus Polska Sp. z o.o.

    Wroclaw, Poland

  • FutureMeds Sp. z o.o.

    Wroclaw, Poland

  • Centrum Medyczne Pratia Poznan

    Skórzewo, Greater Poland Voivodeship, Poland

  • Centrum Medyczne Pratia Poznan

    Skórzewo, Greater Poland Voivodeship, Poland

  • Synexus Polska Sp. z o.o.

    Katowice, Silesian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.